$4.87
Today
as of Jul 22, 16:51 ET
Last 30 days
Recent Press Releases & News
What Makes Lexeo Therapeutics (LXEO) One of The Best Stocks Under $10 That Could Triple
Is Lexeo Therapeutics, Inc. (LXEO) Stock Still a Gene Therapy Opportunity After Analyst Valuation Update?
Lexeo Therapeutics Announces Publication in JAMA Cardiology of Phase I/II Data for LX2006 in Friedreich Ataxia
Overview
52-week range
$2.90
$11
24% of range
Avg surprise (last 3)
-1.2%
Avg reaction (last 2)
+1.4%
50% positive
Latest IV / EM
94%
EM ±21.6% · $5 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Mon May 11, 2026 | Mar/2026 | $-0.25 | $-0.29 | +13.8% | +74.8% | +5.0% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.33 | — | — | — | — | financials |
| Thu Aug 14, 2025 | Jun/2025 | $-0.60 | $-0.64 | +6.2% | — | — | earnings |
| Mon May 12, 2025 | Mar/2025 | $-0.99 | $-0.80 | -23.8% | — | -2.2% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.89 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.64 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.77 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-12.36 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-8.30 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Aug 13, 2026 | Jun/2026 | OTHER | -$0.30 | -$0.60 | +50.0% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-22M | — | $-22M | $-31M | $-34M | — | $-32M | $-24M |
| Net income | $-20M | — | $-20M | $-26M | $-33M | — | $-29M | $-21M |
| EPS (diluted) | $-0.25 | — | $-0.33 | $-0.60 | $-0.99 | — | $-0.89 | $-0.64 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $72M | $63M | $41M | $35M | $29M | $35M | $157M | $175M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $201M | $188M | $128M | $140M | $105M | $126M | $159M | $177M |
| Total assets | $250M | $269M | $144M | $176M | $126M | $147M | $174M | $192M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $19M | $22M | $23M | $38M | $38M | $30M | $35M | $27M |
| Total equity | $231M | $247M | $121M | $138M | $88M | $117M | $139M | $165M |